Literature DB >> 17661167

4G/5G polymorphism of PAI-1 gene and Alu-repeat I/D polymorphism of TPA gene in Turkish patients with polycystic ovary syndrome.

Muammer Karadeniz1, Mehmet Erdogan, Afig Berdeli, Fusun Saygili, Candeger Yilmaz.   

Abstract

PURPOSE: Polycystic ovary syndrome (PCOS) is one of the most encountered endocrine malfunctions. PCOS patients have enhanced activation of the blood coagulation system.
METHODS: Eighty-six young women with PCOS and 70 healthy control women were included in our study. PCOS patients and controls were matched for age, body mass index, and allele frequency. Genetic analysis of TPAI and PAI-1 were performed in all subjects. RESULTS AND
CONCLUSIONS: No statistically significant differences have been detected about the ratios of genotypes resulting from PAI-1 promotor 4G/5G gene polymorphism. PAI-1 765 4G/5G gene polymorphism and TPA gene's Alu-repeat insertion/deletion (I/D) polymorphism ratios were not different from the controls. In this study it is shown by the analysis of TPA gene's Alu-repeat insertion/deletion (I/D) polymorphism the PCOS patients with genotype II had lowers total cholesterol and LDL-cholesterol levels.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17661167      PMCID: PMC3454952          DOI: 10.1007/s10815-007-9160-7

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  44 in total

1.  Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome.

Authors:  C J Glueck; P Wang; R N Fontaine; L Sieve-Smith; T Tracy; S K Moore
Journal:  Metabolism       Date:  1999-12       Impact factor: 8.694

2.  Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risks of myocardial infarction among middle-aged men.

Authors:  P M Ridker; M T Baker; C H Hennekens; M J Stampfer; D E Vaughan
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-09       Impact factor: 8.311

3.  Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam Study.

Authors:  J G van der Bom; P de Knijff; F Haverkate; M L Bots; P Meijer; P T de Jong; A Hofman; C Kluft; D E Grobbee
Journal:  Circulation       Date:  1997-06-17       Impact factor: 29.690

4.  Promoter (4G/5G) plasminogen activator inhibitor-1 genotype in Pima Indians: relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome.

Authors:  L J McCormack; D K Nagi; M H Stickland; M W Mansfield; V Mohamed-Ali; J S Yudkin; W C Knowler; P J Grant
Journal:  Diabetologia       Date:  1996-12       Impact factor: 10.122

5.  Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome.

Authors:  M Sampson; C Kong; A Patel; R Unwin; H S Jacobs
Journal:  Clin Endocrinol (Oxf)       Date:  1996-11       Impact factor: 3.478

6.  Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin.

Authors:  Charles J Glueck; Ping Wang; Naila Goldenberg; Luann Sieve
Journal:  Clin Appl Thromb Hemost       Date:  2004-10       Impact factor: 2.389

7.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

8.  Blood coagulation and fibrinolysis in obese NIDDM patients.

Authors:  G Avellone; V Di Garbo; R Cordova; G Rotolo; G Abruzzese; G Raneli; R De Simone; G D Bompiani
Journal:  Diabetes Res       Date:  1994

9.  The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels.

Authors:  Evanthia Diamanti-Kandarakis; Gaetano Palioniko; Krystallenia Alexandraki; Angeliki Bergiele; Thenia Koutsouba; Michael Bartzis
Journal:  Eur J Endocrinol       Date:  2004-06       Impact factor: 6.664

10.  Alu-repeat polymorphism in the tissue-type plasminogen activator (tPA) gene does not affect basal endothelial tPA synthesis.

Authors:  Y van den Eijnden-Schrauwen; N Lakenberg; J J Emeis; P de Knijff
Journal:  Thromb Haemost       Date:  1995-10       Impact factor: 5.249

View more
  6 in total

1.  Plasminogen activator inhibitor-1 -675 4G/5G polymorphism and polycystic ovary syndrome risk: a meta analysis.

Authors:  Ying Liu; Mei-Guo Sun; Rong Jiang; Rui Ding; Zhen Che; Yan-Yan Chen; Ci-Jiang Yao; Xiao-Xia Zhu; Ji-Yu Cao
Journal:  J Assist Reprod Genet       Date:  2014-01-17       Impact factor: 3.412

2.  Apolipoprotein E gene polymorphism and polycystic ovary syndrome patients in Western Anatolia, Turkey.

Authors:  Sevki Cetinkalp; Muammer Karadeniz; Mehmet Erdogan; Ayhan Zengi; Vildan Cetintas; Asli Tetik; Zuhal Eroglu; Buket Kosova; A Gokhan Ozgen; Fusun Saygili; Candeger Yilmaz
Journal:  J Assist Reprod Genet       Date:  2008-12-05       Impact factor: 3.412

3.  Genetic polymorphisms of FSHR, CYP17, CYP1A1, CAPN10, INSR, SERPINE1 genes in adolescent girls with polycystic ovary syndrome.

Authors:  Tugba Unsal; Ece Konac; Ediz Yesilkaya; Akin Yilmaz; Aysun Bideci; Hacer Ilke Onen; Peyami Cinaz; Adnan Menevse
Journal:  J Assist Reprod Genet       Date:  2009-04-22       Impact factor: 3.412

4.  Effect Of G2706A and G1051A polymorphisms of the ABCA1 gene on the lipid, oxidative stress and homocystein levels in Turkish patients with polycystıc ovary syndrome.

Authors:  Muammer Karadeniz; Mehmet Erdoğan; Zengi Ayhan; Murat Yalcin; Murat Olukman; Sevki Cetinkalp; Gulinnaz E Alper; Zuhal Eroglu; Asli Tetik; Vildan Cetintas; Ahmet G Ozgen; Fusun Saygili; Candeger Yilmaz
Journal:  Lipids Health Dis       Date:  2011-10-28       Impact factor: 3.876

5.  Alu DNA Polymorphism of Human Tissue Plasminogen Activator (tPA) Gene in Diabetic Jordanian Patients

Authors:  Salem R. Yasin; Hussam H. AlHawari; Abeer A. Alassaf; Maysa M. Khadra; Zainab A. Al-Mazaydeh; Ala'a F. Al-Emerieen; Lubna H. Tahtamouni
Journal:  Iran Biomed J       Date:  2019-05-20

Review 6.  Functional genetic polymorphisms and female reproductive disorders: Part I: Polycystic ovary syndrome and ovarian response.

Authors:  M Simoni; C B Tempfer; B Destenaves; B C J M Fauser
Journal:  Hum Reprod Update       Date:  2008-07-04       Impact factor: 15.610

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.